Hossein Panjideh
Overview
Explore the profile of Hossein Panjideh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
60
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Panjideh H, Niesler N, Weng A, Fuchs H
Toxins (Basel)
. 2022 Oct;
14(10).
PMID: 36287991
The authors wish to make corrections to their paper [...].
2.
Panjideh H, Niesler N, Weng A, Fuchs H
Toxins (Basel)
. 2022 Jul;
14(7).
PMID: 35878216
Immunotoxins do not only bind to cancer-specific receptors to mediate the elimination of tumor cells through the innate immune system, but also increase target cytotoxicity by the intrinsic toxin activity....
3.
Fuchs H, Niesler N, Trautner A, Sama S, Jerz G, Panjideh H, et al.
Biomedicines
. 2017 May;
5(2).
PMID: 28536357
Protein-based targeted toxins play an increasingly important role in targeted tumor therapies. In spite of their high intrinsic toxicity, their efficacy in animal models is low. A major reason for...
4.
Panjideh H, Muller G, Koch M, Wilde F, Scheu S, Moldenhauer G, et al.
Int J Cancer
. 2014 Apr;
135(11):2623-32.
PMID: 24729415
Bispecific antibodies are promising agents for immunotherapy. Here, we describe a quadroma-based trifunctional bispecific antibody binding the chemokine receptor CXCR5 and the T-cell antigen CD3 that efficiently prevents tumor growth...
5.
Schellmann N, Panjideh H, Fasold P, Bachran D, Bachran C, Deckert P, et al.
J Immunother
. 2012 Aug;
35(7):570-8.
PMID: 22892453
In adults, endothelial cell division occurs only in wound healing, during menstruation, or in diseases such as wet age-related macular degeneration or development of benign or malignant tissues. Angiogenesis is...
6.
Panjideh H, Da Silva Coelho V, Dernedde J, Bachran C, Forster G, Franke J, et al.
Int J Oncol
. 2008 Mar;
32(4):925-30.
PMID: 18360720
In antibody-directed enzyme-prodrug therapy (ADEPT), an antibody-bound enzyme localizes to tumor tissue, where it selectively converts a subsequently administered non-toxic prodrug into a cytotoxic drug. A33scFv::CDy is a bifunctional fusion...
7.
Panjideh H, Coelho V, Dernedde J, Fuchs H, Keilholz U, Thiel E, et al.
Bioprocess Biosyst Eng
. 2008 Feb;
31(6):559-68.
PMID: 18253756
Recombinant antibody fusion constructs with heterologous functional domains are a promising approach to new therapeutic targeting strategies. However, expression of such constructs is mostly limited to cost and labor-intensive mammalian...
8.
Petrausch U, Dernedde J, Coelho V, Panjideh H, Frey D, Fuchs H, et al.
Protein Eng Des Sel
. 2007 Nov;
20(12):583-90.
PMID: 18033820
Chemical conjugates of monoclonal antibodies with fluorophores or enzymes have long been used for diagnostic purposes and experimental therapeutic approaches. Recombinant technology allows for the design and expression of tailored...
9.
Coelho V, Dernedde J, Petrausch U, Panjideh H, Fuchs H, Menzel C, et al.
Int J Oncol
. 2007 Sep;
31(4):951-7.
PMID: 17786329
Antibody-directed enzyme-prodrug therapy (ADEPT) aims at improving the specificity of conventional chemotherapy by employing artificial antibody-enzyme constructs to convert a non-toxic prodrug into a cytotoxic agent specifically localized to the...